Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.2% – Here’s Why

Zenas BioPharma, Inc. (NASDAQ:ZBIO)’s share price fell 6.2% during trading on Monday . The company traded as low as $21.48 and last traded at $22.54. 132,541 shares traded hands during mid-day trading, a decline of 86% from the average session volume of 933,859 shares. The stock had previously closed at $24.04.

Analyst Ratings Changes

A number of analysts recently issued reports on ZBIO shares. Evercore started coverage on Zenas BioPharma in a report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price target for the company. Morgan Stanley cut shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $37.00 to $19.00 in a research note on Monday, January 5th. HC Wainwright restated a “buy” rating and set a $44.00 target price on shares of Zenas BioPharma in a report on Tuesday, February 10th. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 target price on shares of Zenas BioPharma in a report on Tuesday, January 6th. Finally, Wall Street Zen raised Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.83.

Zenas BioPharma Trading Down 3.6%

The company has a fifty day moving average of $22.48 and a two-hundred day moving average of $27.07. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -3.26 and a beta of -1.96.

Insider Buying and Selling at Zenas BioPharma

In related news, Director Patricia L. Allen purchased 15,700 shares of Zenas BioPharma stock in a transaction on Thursday, February 12th. The shares were purchased at an average price of $24.85 per share, for a total transaction of $390,145.00. Following the transaction, the director owned 15,700 shares of the company’s stock, valued at approximately $390,145. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Hongbo Lu purchased 25,985 shares of Zenas BioPharma stock in a transaction on Wednesday, February 11th. The stock was bought at an average price of $22.50 per share, with a total value of $584,662.50. Following the completion of the acquisition, the director directly owned 347,968 shares of the company’s stock, valued at approximately $7,829,280. This trade represents a 8.07% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 202,845 shares of company stock worth $3,747,185. Insiders own 16.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. SR One Capital Management LP boosted its stake in shares of Zenas BioPharma by 2.6% during the 4th quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock valued at $182,924,000 after purchasing an additional 126,315 shares in the last quarter. NEA Management Company LLC increased its position in Zenas BioPharma by 28.9% in the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock worth $127,928,000 after buying an additional 789,500 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of Zenas BioPharma by 45.9% during the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock worth $98,603,000 after acquiring an additional 853,740 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Zenas BioPharma by 25.0% during the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after buying an additional 290,307 shares during the last quarter. Finally, Polar Capital Holdings Plc purchased a new position in Zenas BioPharma during the 4th quarter worth $38,402,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.